Amicus Therapeutics And Blackstone Enter Into $430 Million Strategic Financing Collaboration
Round Type
Funding Round
PrincetonBiotechnologyHealth CareTherapeuticsDescription
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone (NYSE: BX). As part of the collaboration, Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancing of existing debt and a $30 million strategic investment in Amicus’s common stock. The financing collaboration allows Amicus to grow revenues and move toward profitability while delivering on its mission for patients and its vision of being one of the leading biotechnology companies focused on rare diseases.
Quick answer
Amicus Therapeutics raised an undisclosed amount in a Funding Round round, dated October 2, 2023. Amicus Therapeutics is based in Princeton, New Jersey, United States.
- How much did Amicus Therapeutics raise?
- Amicus Therapeutics raised an undisclosed amount in a Funding Round round on October 2, 2023.
- What does Amicus Therapeutics do?
- We are leveraging our innovative technology platforms to develop treatments for human genetic diseases.
- Where is Amicus Therapeutics based and how big is it?
- Amicus Therapeutics is based in Princeton, New Jersey, United States. Fundz records about 500 employees.
- Who are the decision-makers at Amicus Therapeutics?
- Fundz holds 1 contact at Amicus Therapeutics, including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Amicus Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- On Target Laboratories raised $30M (Funding Round) on November 16, 2023.
- MAIA Biotechnology raised $4.9M (Seed) on November 15, 2023.
- EyeBio raised an undisclosed amount (Series A) on November 14, 2023.
- Nouscom raised $72M (Series C) on November 14, 2023.
- Vittoria raised $15M (Funding Round) on November 14, 2023.
- MBrace Therapeutics raised $85M (Series B) on November 14, 2023.
Who to call at Amicus Therapeutics, and when
A new round usually means Amicus Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Amicus Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Amicus Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Amicus Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Amicus Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Amicus Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.